SV

Street Verdict

Analyst Scorecard

A record of what Jefferies Analysis said publicly, with the source. Not advice.

“Bullish on Piramal Pharma, setting a target of ₹260, indicating an almost 30% potential upside. The stock's valuation discount relative to peers makes it an attractive bet, despite a 15% drop over the past year.”

Jefferies Analysis’s track record (trackable calls only): 153 graded calls · 95% CI 37–53%

Piramal Pharma LtdBullishCalled 15 Sep 2025Graded 15 Sep 2026
Verdict:MISS

R4 TARGET_CALL: entered ₹205.63 on 2025-09-16 (next trading session's close); neither target nor stop reached by window end 2026-09-15. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.

How it played out

How this is worked out
Time to target
The target was not reached on a close inside the window.
Worst close against it
The closing price went as far as 35.19% against the call up to 15 Sep 2026, when the call was decided, measured from the entry price. Closing prices only; an intraday dip is never counted.

From the entry the grade used, on closing prices. This is a record of one past call and is not advice.

Read the original articleSee Jefferies Analysis’s full track record